These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17630647)

  • 1. Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks.
    de Matas M; Shao Q; Silkstone VL; Chrystyn H
    J Pharm Sci; 2007 Dec; 96(12):3293-303. PubMed ID: 17630647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
    de Matas M; Shao Q; Richardson CH; Chrystyn H
    Eur J Pharm Sci; 2008 Jan; 33(1):80-90. PubMed ID: 18035525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems.
    Silkstone VL; Dennis JH; Pieron CA; Chrystyn H
    J Aerosol Med; 2002; 15(3):251-9. PubMed ID: 12396413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.
    Silkstone VL; Corlett SA; Chrystyn H
    Br J Clin Pharmacol; 2002 Aug; 54(2):115-9. PubMed ID: 12207629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks.
    de Matas M; Shao Q; Biddiscombe MF; Meah S; Chrystyn H; Usmani OS
    Eur J Pharm Sci; 2010 Dec; 41(5):707-15. PubMed ID: 20932900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged.
    Silkstone VL; Tomlinson HS; Corlett SA; Chrystyn H
    Br J Clin Pharmacol; 2000 Sep; 50(3):281-4. PubMed ID: 10971315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation.
    Chege JK; Chrystyn H
    Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
    Waldrep JC; Berlinski A; Dhand R
    J Aerosol Med; 2007; 20(3):310-9. PubMed ID: 17894537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers.
    Sidler-Moix AL; Dolci U; Berger-Gryllaki M; Pannatier A; Cotting J; Di Paolo ER
    Pediatr Crit Care Med; 2013 Feb; 14(2):e98-102. PubMed ID: 23287904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse nebulization in pneumatic devices.
    GradoĊ„ L; Sosnowski TR; Podolec Z
    Int J Occup Saf Ergon; 1999; 5(1):31-42. PubMed ID: 10602637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs.
    Nazir J; Barlow DJ; Jayne Lawrence M; Shrubb I
    J Pharm Sci; 2005 Sep; 94(9):1986-97. PubMed ID: 16052546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.
    Richardson CH; de Matas M; Hosker H; Mukherjee R; Wong I; Chrystyn H
    Pharm Res; 2007 Nov; 24(11):2008-17. PubMed ID: 17510755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
    Chrystyn H
    Br J Clin Pharmacol; 1996 Aug; 42(2):257-8. PubMed ID: 8864330
    [No Abstract]   [Full Text] [Related]  

  • 15. A system for the production and delivery of monodisperse salbutamol aerosols to the lungs.
    Biddiscombe MF; Usmani OS; Barnes PJ
    Int J Pharm; 2003 Mar; 254(2):243-53. PubMed ID: 12623200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of salbutamol pressurized metered-dose inhaler administered via small-volume spacer devices in intubated, spontaneously breathing rabbits.
    Dubus JC; Rhem R; Monkman S; Dolovich M
    Pediatr Res; 2001 Sep; 50(3):384-9. PubMed ID: 11518826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.
    Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A
    Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salbutamol relative lung and systemic bioavailability of large and small spacers.
    Mazhar SH; Chrystyn H
    J Pharm Pharmacol; 2008 Dec; 60(12):1609-13. PubMed ID: 19000365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling of in-vitro and in-vivo performance of aerosol emitted from different vibrating mesh nebulisers in non-invasive ventilation circuit.
    Rabea H; Ali AM; Salah Eldin R; Abdelrahman MM; Said AS; Abdelrahim ME
    Eur J Pharm Sci; 2017 Jan; 97():182-191. PubMed ID: 27866986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.